Objectives
Small cell cervical cancer (SCCC) is an extremely rare and aggressive form of cervical cancer, accounting for only 1% of all cervical cancer cases, or ~150 cases/yr. 70% of patients will recur, even when diagnosed with early stage disease and there are few therapeutic options in this setting. We evaluated tumor samples obtained from a large repository to determine prevalent targetable molecular aberrations in these rare tumors.
Download Publication